Purpose. Staphylococcus epidermidis ATCC12228 lipoteichoic acid (LTA) inhibits TNFa production from keratinocytes that are activated with poly I:C. However, this effect has not been proven in clinical or commensal isolates.
INTRODUCTION
The microbiota of different organs are involved in homeostasis and the prevention of infection by pathogens. However, changes in the microbiota composition of an organ (dysbiosis) contribute to the development of inflammatory disease. With respect to the microbiota of the skin, some pathogens contribute to an inflammatory or antiinflammatory process [1] . Propionibacterium acnes participates in the inflammation of the skin, producing acne vulgaris [2] , and the genera Corynebacterium and Staphylococcus control inflammation of the skin. Comparative studies between healthy and psoriatic skin have shown changes in the composition of the microbiota, which mainly consist of a decrease in Propionibacterium acnes and actinobacteria, as well as an increase in Firmicutes in psoriasis [3] .
S. epidermidis is a commensal in the skin, and its contribution as a microbiota has not been extensively explored. Recent studies indicate that S. epidermidis functions in the activation of the skin immune system [4, 5] ; S. epidermidis induces the production of antimicrobial peptides [6] , IL-17A [7] and regulatory T cells [8] on the skin. The components of the cell wall or cytoplasmic membrane of S. epidermidis are involved in the immunomodulatory response; one of these is lipoteichoic acid (LTA). S. epidermidis LTA inhibits the production of tumour necrosis factor a (TNFa) as well as IL-6 from keratinocytes activated with poly I:C-TLR3 [9] . In addition, S. epidermidis LTA inhibits skin inflammation caused by P. acnes by inducing miR-143 microRNA [10] . S. epidermidis LTA is anchored in the cytoplasmic membrane, and it extends to the cell wall. However, it is proposed that S. epidermidis releases LTA into the environment as a shorter-chain LTA [11] . We believe that it is difficult to predict that LTA is released in all strains, or in all clinical and commensal isolates, because S. epidermidis shows high genetic diversity [12] , which makes it difficult to determine its behaviour. Therefore, the focus of this work was to explore the release of LTA in different populations of clinical isolates or commensals and to propose a mechanism for the release of this compound.
METHODS Isolates of Staphylococcus epidermidis
A collection of isolates of S. epidermidis was obtained from ocular infections (OIs) from 1995 to 2000 at the Institute of Ophthalmology Conde de Valenciana, Mexico City, Mexico. Ophthalmic samples were obtained from patients diagnosed with an OI (n=56) by an ophthalmologist. Corneal ulcer samples were obtained by corneal scraping, while samples of conjunctivitis and staphylococcal blepharitis were obtained by swabbing. Vitreous samples from patients with endophthalmitis were mainly collected by vitrectomy. Samples from healthy skin (HS; n=35) and conjunctiva (HC; n=32) were collected by swabbing. All of the clinical samples were spread on blood chocolate agar and mannitol salt agar (Becton, Dickinson and Company, NJ, USA) plates and incubated at 37 C for 12 h. In the case of OI isolates, we only considered plates with an axenic culture, and these colonies were cultured on mannitol salt agar. Identification of S. epidermidis was performed with the Vitek Jr semiautomated system (Biom erieux, Craponne, France) using the identification cards GPS-101 and V-1305 for Gram-positive bacteria. Based on the Declaration of Helsinki, all patients signed medical informed consent forms to participate in this study, and the study was approved by the ethics committee of National School of Biological Sciences of the 'Instituto Polit ecnico Nacional' Mexico.
The <10 kDa fractions of the supernatants of S. epidermidis Different S. epidermidis isolates were cultured in 5 ml of tryptic soy broth medium (TSB; Becton, Dickinson and Company) and incubated at 37 C overnight. Subsequently, the culture was diluted 1 : 200 in TSB medium and incubated at 37 C for 16 h. The cultures were then centrifuged at 6000 g for 10 min, and the supernatants were transferred to a new microtube. The supernatants were filtered with an Amicon Ultra 10 kDa (Millipore, Billerica, MA, USA) to obtain the <10 kDa fraction. The <10 kDa fractions were stored at À70 C until use. The amount of protein in the <10 kDa fractions was determined by the Bradford method.
Inhibition test with the <10 kDa fraction in human keratinocyte HaCaT cultures Human HaCaT keratinocyte cultures were established in 24-well microplates using Dulbecco's Modified Eagle's Medium (DMEM; Gibco, Waltham, MA, USA) supplemented with 10 % fetal bovine serum, 4.0 mg l À1 gentamicin and 2.5 µg l À1 fungizone. HaCaT keratinocyte cultures were incubated at 37 C in the presence of 5 % CO 2 until they reached 70 % confluence. Subsequently, the supplemented DMEM was withdrawn and 1 ml of DMEM supplemented with an antibiotic was added; this was followed by incubation at 37 C with 5 % CO 2 for an additional 12 h. Subsequently, the cultures were stimulated with 1 ml of the new DMEM containing 10 µg ml À1 of poly I:C plus 5 µg of the total protein of the <10 kDa fraction. The controls consisted of HaCaT cells stimulated with 10 µg ml À1 poly I:C, HaCaT cells stimulated with 10 µg ml À1 of poly I:C plus 10 µg ml
À1
of Staphylococcus aureus LTA or HaCaT cells stimulated with 5 µg of the total protein from the TSB medium. The stimulation time was 12 h, and later the supernatant was collected for determination of the TNFa.
Quantification of TNFa by ELISA TNFa production was quantified in the supernatant of the stimulated keratinocyte cultures with an ELISA kit for human TNFa (Invitrogen, Calsbad, CA, USA) following the manufacturer's protocol. ELISA was carried out in a 96-well plate covered with anti-TNFa antibodies. One-hundred microlitres of the supernatant was placed in each well, and the plate was incubated for 2 h at room temperature. Subsequently, the wells were washed four times with phosphate-buffered saline (PBS; Thermo Fisher Scientific, Waltham, MA, USA), and 100 µl of the second anti-TNFa antibody conjugated to biotin was added before the plate was incubated for 1 h at room temperature. The wells were washed, and 100 µl of peroxidase-streptavidin (SigmaAldrich, St Louis, MO, USA) was added for 30 min. Detection was performed with tetramethylbenzidine (TMB; Sigma-Aldrich) for 30 min at room temperature in the dark. The absorbances were acquired in an ELISA reader at 450 nm. To determine the concentration of TNFa in the supernatants of the keratinocytes, a standard TNFa curve in triplicate was performed with the following concentrations: 1000, 500, 250, 125, 62.5, 31.2 and 15.6 pg ml
. The criteria for inhibition or non-inhibition of TNFa production were: showing a higher or lower TNFa concentration, respectively, compared to the mean of the control with HaCaT cells stimulated with poly I:C.
Western blot analysis
Western-blot assays were performed to determine the LTA in the <10 kDa fraction obtained from the supernatant of the S. epidermidis isolates from HS (n=3), HC (n=4) and OI (n=4). Briefly, the <10 kDa fractions and purified S. aureus LTA (Sigma-Aldrich) were analysed by SDS-PAGE using 12 and 10 % polyacrylamide gels. The proteins were transferred onto a nitrocellulose (NC) membrane (0.2 µm pore size; Bio-Rad Laboratories, Hercules, CA, USA), blocked with 10 % non-fat dried milk in PBS/0.1 % Tween 20 (PBS/T) overnight at 4 C, washed with PBS/T and incubated with a primary mouse anti-LTA Mab 55 (1 : 500 dilution; Hycult Biotech, PB Uden, Netherlands; catalogue HM2048; antigens: microbial mixture of Streptococcus sobrims HG961, HG962, HG970 and HG977) [13] for 18 h at 4 C. After incubation for 2 h at room temperature with a peroxidaseconjugated rabbit anti-mouse secondary antibody (1 : 3000 dilution; Bio-Rad Laboratories), the reactive bands were developed using a chemiluminescence system (SuperSignal West Pico chemiluminescent substrate; Thermo Scientific Pierce, Waltham, MA, USA). The images were captured with a ChemiDoc XRS system (Bio-Rad Laboratories) and analysed using Quantity One software (Bio-Rad Laboratories). Sterile TSB was used as a specificity control. Purified staphylococcal LTA was used as a positive control for the Western blot. These experiments were performed in duplicate, with similar results.
LTA staining for flow cytometry S. epidermidis was cultured overnight in 2 ml of TSB at 37 C with shaking and was then diluted in fresh TSB to reach an OD 625 of 0.1, after which growth continued at 37 C with shaking. At 2, 5, 16 and 24 h, 1 ml of the culture was harvested by centrifugation, washed twice with PBS and adjusted to 10 7 c.f.u. ml 
Determination of LTA by chromatography coupled to mass
The supernatants utilized were those obtained from the bacterial growth assay described in the 'LTA staining for flow cytometry' section above. Electrospray ionization mass spectrometry (ESI-MS) was performed using a SCIEX 4000 QTRAP mass spectrometer and was examined by the negative ion electrospray mass. Electrospray ionization was achieved at a temperature of 500 C and a pressure of 30 psi for curtain gas as well as ion source gases 1 and 2. The collision energy in the ion trap was 40 electronvolts. The liquid samples were diluted by adding a two-fold volume of acetonitrile/water (50/50 containing 10 mM formic acid) to a concentration of 0.01 mg ml À1 (10 ppm) for direct infusion at a rate of 0.5 ml h
À1
. Separation by HPLC was carried out on a Hypersil octaldecyl silane column (250Â4.6 mm; 3 µm).
Expression of the ugtp, ltaA and ltaS genes by RT-qPCR The isolates were grown for 5 and 16 h in TSB medium, and bacteria were harvested to obtain total RNA. Later, total RNA was extracted using a TRIzol kit (Invitrogen). The procedure was performed in accordance with the manufacturer's instructions. The total RNA extracted was treated with RNAse-free DNAse I (Invitrogen) for 30 min at room temperature and was repurified using a TRIzol kit. For the teverse transcriptase (RT) reaction, total RNA (3 µg) with 0.5 µg of oligo-hexamers (Invitrogen) was denatured at 70 C for 10 min. Then, Â1 single-strand buffer, 0.5 mM DTT, 10 mM of each dNTP and 200 U of MMLV reverse transcriptase (Invitrogen) were added. The RT reactions were performed at 42 C for 1 h. The expression levels of RNA were analysed by real-time qPCR with the Fast SYBR Green qPCR kit (Applied Biosystems, Waltham, MA, USA) according to the manufacturer's instructions. The relative quantities of the ugtP, ltaA and ltaS genes and constitutive 16S rRNA gene (Table 1) were calculated by a standard curve using genomic DNA from S. epidermidis. The quantity of mRNA was normalized with the quantity of 16S rRNA. The results are expressed as the average of triplicates, and the standard deviations are represented by error bars.
RESULTS
Effect of the <10 kDa fraction on the HaCaT keratinocytes activated with poly I:C The <10 kDa fraction of the S. epidermidis isolates from OI (n =56), HS (n=35) and HC (n=32) were obtained and tested on HaCaT keratinocytes stimulated with poly I:C for TNFa production. Three populations were obtained: isolates with an inhibitory effect on TNFa production (TNFa-inhibitor isolates), isolates without an inhibitory effect on TNFa production (TNFa non-inhibitor isolates) and isolates with a similar behaviour to the control (Fig. 1aÀc) . In the isolates from OI, 80.4 % of the <10 kDa fractions had an inhibitory effect on the production of TNFa. In contrast, in isolates from HC and HS, 68.8 and 54.3 % had an inhibitory effect, respectively (Table 2 ). These results demonstrate that there is a different behaviour among isolates from the same source of isolation, indicating that not all of the isolates have the same ability to inhibit TNFa production from HaCaT keratinocytes activated with poly I:C. A representative sample of the TNFa-inhibitor (42HS, 131HC, 1085OI and 2050OI) and TNFa non- 16   146   139  215  1085  2050  56  93  1668  58  1980  2038  1784-2  1682  2022  106  61  1085  50  1664  1848  60  105  146  214  160  144  1774  1689  54  199  2009  155  1864  1700  35  90  1654  213  1864  1701  149  47  1655  68  95  96  983  53  71  2938  1660  156  51  1864-2  159  63  98   131  118  152  137  132  97  120  129  151  114  22  29  25  106  103  100  144  23  128  30  35  10  94  8  17  7  69  11  14  88  9   39  44  45  20  37  79  58  54  87  83  85  71  91  81  84 inhibitor (37HS, 146HC, 88HC, 9HC, 98OI and 63OI) isolates from each source of isolation was assayed in triplicate to verify statistical significance; furthermore, S. aureus LTA and TSB media were included as controls. The same result was obtained, and a significant difference between the <10 kDa fractions with an inhibitory and non-inhibitory effect on TNFa production was observed. In addition, S. aureus LTA inhibited TNFa production compared to the TSB medium (Fig. 2aÀc) .
To verify the presence of LTA in the <10 kDa fractions, a Western blot was performed using an anti-LTA antibody. A band with a similar molecular weight to S. aureus LTA (lanes 1 and 2, Fig. 3a) was detected in the <10 fraction of the 2050OI isolate ( lanes 3 and 4, Fig. 3a ). In the <10 kDa fractions, one band was detected in the TNFa-inhibitor isolates but it was not detected or was poorly detected in the TNFa non-inhibitor isolates (Fig. 3b) . This result indicates that the inhibition of the production of TNFa is due to the abundance of LTA in the <10 kDa fraction.
Release of LTA during bacterial growth
To study the release of LTA in the culture medium, the amount of LTA was evaluated in the 1085OI isolate (with high LTA in the <10 kDa fraction) and 37HS isolate (no LTA in the <10 KDa fraction) during bacterial growth. Flow cytometry, using the anti-LTA antibody, showed that the 1085OI isolate contained a low amount of LTA in its cytoplasmic membrane throughout the growth kinetics (P>0.05). In contrast, in the 37HS isolate, at 16 h of growth there was a significant increase in the amount of LTA in its cytoplasmic membrane (Fig. 4) , and the same result was observed in the control strain, S. epidermidis ATCCC12228 (data not shown).
To confirm that LTA is released into the culture medium, LTA was detected by ESI-MS in the supernatants of the cultures mentioned above. A representative test is shown in Fig. 5 . In the supernatant of the 16 h growth of the 1085OI isolate, two peaks were observed with retention times of 10.29 and 10.30 min (Fig. 5a ), and these were not observed in the 37HS isolate (Fig. 5c ). However, both peaks were detected in standard S. aureus LTA (Fig. 5e) , suggesting that the two peaks correspond to LTA. Lambert et al. (2000) found two prominent mass/charge ratio (m/z) peaks of 804 and 1206 in several isolates of S. epidermidis, corresponding to a short-length LTA denominated as lipid S [11] . When the composition of the m/z peaks with a retention time of 10.20 and 10.30 min was determined, the supernatant of the 1085OI isolate presented the two m/z peaks of 804 and 1206 (Fig. 5b) , which did not occur with the 37HS isolate (Fig. 5d) or the standard S. aureus LTA (Fig. 5f) ; however, the m/z ratio of the S. aureus LTA corresponded to that reported by Lambert et. al. [11] . After obtaining the LTA patterns, LTA was detected in the supernatants of the growth kinetics samples. In the 1085OI isolate, a shortlength LTA (lipid S) was detected at 5, 16 and 24 h at concentrations of 21.4, 32.4 and 12.5 ng ml
À1
, respectively. In the 37HS isolate, short-length LTA was not detected throughout its bacterial growth. In the strain S. epidermidis ATCCC12228, short-length LTA was detected until 16 h of growth at 7.6 ng ml À1 (Figs S1-S11, available in the online Supplementary Material).
Expression levels of the genes involved in LTA synthesis
To associate the release of LTA with its cytoplasmic synthesis, the expression levels of the ugtP, ltaA and ltaS genes were determined during bacterial growth. The 1085OI isolate and ATCC12228 strain showed similar levels of expression of the three genes studied at 5 and 16 h of bacterial growth. However, the 37HS isolate presented a low expression level for the ltaS gene at the two evaluation time points (5 and 16 h; Fig. 6 ), and the expression levels of the ugtP and ltaA genes were similar to those obtained in the 1085OI isolate.
DISCUSSION
The LTA of Gram-positive bacteria is an abundant and important component in cellular homeostasis. The functions attributable to LTA are regulation of the net charge of the cell wall to avoid attack from cationic antimicrobial peptides on the cytoplasmic membrane, regulation of cellular division, and resistance against heat stress and low osmolality. Regarding its immunological function, S. aureus LTA interacts with TLR2 and the TLR coreceptor CD14 [14, 15] to activate the innate immune response. However, it is reported that other proteins, such as neutrophil-activating peptide 2, prohibitin-2, alpha-1-anti-trypsin, histidine-rich glycoprotein, apolipoproteins, complements and coagulation factor, bind to LTA to activate the innate immune response [16] . LTA inhibits platelet-dependent inflammatory mediator release and platelet-monocyte aggregation [17] . LTA-stimulated human peripheral blood mononuclear cells (PBMCs) produce MCP-1/CCL2, IL-6 and IL-1b [18] . *The percentages were obtained in reference to the mean of the controls of the keratinocytes stimulated with poly I:C from each source of isolation.
Pam3Cys stimulation yields enhanced secretion of CCL20, CCL2, MMP9 and IL-8 in human primary keratinocytes (HPKs), whereas stimulation with PGN or LTA does not show effects or only shows slight effects [19] . With reference to S. epidermidis LTA, little is known. Recently, Lai et al. [9] demonstrated that S. epidermidis LTA inhibited the production of TNFa for keratinocytes activated with poly I:C [9] . However, these authors used the <10 kDa fractions from a few strains, three strains from S. epidermdis (1457, ATCC1228 and RP62A) and two from S. aureus (Sa113 and Newman). The strains showed an inhibitory effect on the production of TNFa. Moreover, in the S. aureus Rosenbach strain isolated from a hospital, the TNFa inhibitory effect did not occur, which demonstrates that not all clinical isolates have the same TNFa-inhibitory capacity. In this work, we demonstrated that clinical and commensal isolates show different behaviours regarding the inhibition of TNFa production in poly-I:C-activated HaCaT keratinocytes. This result showed that not all of the <10 kDa fractions of the S. epidermidis isolates have the ability to inhibit the TNFa production of keratinocytes. The behavioural diversity of S. epidermidis among the isolates could be explained by the high genetic diversity of the genus [12] . Another relevant result of this work is the fact that there were differences between the three sources of isolates. We obtained a greater proportion of isolates with an inhibitory effect on the ), TSB medium (5 µg total protein) or the <10 kDa fraction (5 µg total protein) of the isolates from healthy skin, 42, 9 and 37 (a); healthy conjunctiva, 131, 146, 88 and 9 (b); and ocular infections, 1085, 2050, 98 and 63 (c). TNFa was determined by ELISA using the supernatants of the keratinocytes. The assays were performed three times and analysed using one-way ANOVA with Tukey's test. The asterisks indicate statistical significance compared with the control (poly-I:C-stimulated keratinocytes). Ns indicates no statistical significance.
production of TNFa in OIs (80.4 %), followed by HC. This suggests that the isolates from OIs release LTA to inhibit the production of TNFa and other cytokines to evade the proinflammatory response and establish the bacterium in the eye. When the different cell types of the skin were tested, keratinocyte cells were the only cells that responded to the effect of LTA, establishing a cellular specificity for this compound [9] . It is not known whether LTA has the same function in the eye.
The behaviour of the two identified populations (the TNFainhibitor and TNFa non-inhibitor isolates) could be because all of the isolates release LTA to the culture medium at the same proportion, but the chemical structure of the LTA is different, or it could be because all of the isolates release LTA at different proportions. The <10 kDa fractions from the TNFa-inhibitor isolates have more LTA (determined by Western blot) than the TNFa non-inhibitor isolates. However, the release of LTA into the culture medium could be due to cell death. To discard this possibility, the release of LTA during the growth of S. epidermidis was analysed. The 1085OI isolate (TNFa-inhibitor) had a low amount of LTA in the cytoplasmic membrane and a high amount of LTA in the supernatant after 5 h of growth, in contrast to that observed in the 37HS isolate (TNFa noninhibitor). This result demonstrates that LTA is released from the onset of growth and is not a product of cell lysis. The results confirm that the release of LTA to the culture medium is the main cause of the effect of LTA on the keratinocyte and that the effect is not due to structural changes of the LTA between the two populations. The amount released from LTA could be attributable to its synthesis. In the TNFa non-inhibitor isolate (37HS), the expression level of the ltaS gene was significantly lower during its growth than that for the TNFa-inhibitor isolate (1085OI), while the expression levels of the ugtP and ltaA genes did not change. Synthesis of LTA in S. aureus is initiated by the glycosyltransferase YpfP (encoded by the ugtP gene), which synthesizes the glycolipid anchor Glc2-DAG from a nucleotide-activated sugar diglucosyl-UDP, and Glc2-DAG is then moved to the outside of the membrane by the flippase LtaA [20] . The GroP (glycerolphosphate) chain is then extended on Glc2-DAG by the repeated addition of GroP subunits derived from the membrane group of the lipid phosphatidylglycerol (PG) by the action of LTA synthase (LtaS) [21] . LtaS is responsible for carrying out elongation of the LTA chain. Therefore, we suggest that the low expression level of the ltaS gene in the 37HS isolate is the reason why there is not a release of LTA to the culture medium, because there is reduced synthesis of LTA and, therefore, low production of LTA in the cytoplasmic membrane. In fact, it has been proposed that LtaS be used as a model for the regulation of LTA synthesis, because this enzyme is cleaved type I signal peptidases, generating inactive LtaS under conditions in which LTA production is no longer required [22] . LTA regulates cell death by activating autolysins. Mutant strains deficient in LTA in the cytoplasmic membrane are more susceptible to autolysin cell death than wild-type strains [23] , indicating the importance of LTA in the cytoplasmic membrane. With these results, we suggest that LTA non-releasing isolates in the culture medium have low ltaS gene expression levels that prevent LTA release, but we do not rule out the possibility of another mechanism being present in S. epidermidis isolates, or the possibility that under certain growth conditions there is an increase in ltaS gene expression, leading to increased LTA release.
Lambert et al. [11] reported a new glycerophosphoglycolipid (named lipid S or short-chain-length exocellular LTA, sce-LTA) produced by S. epidermidis that is released to the culture medium during its microbial growth. The lipid S is a short-chain-length form of cellular LTA, with 6 glycerophosphate units, in contrast to the 40-42 units of LTA; both share the same antigenic determinants and are primarily extracellular [11] . In our supernatants, lower-molecular weight compounds were determined by ESI-MS corresponding to the lipid S. Healthy patients have low serum IgG levels against lipid S and/or LTA, but significantly higher titres are found in the serum of patients with central venous catheter-related sepsis by coagulase-negative staphylococci [11] , orthopaedic prostheses [24] and endocarditis [25] . High levels of IgG indicate high expression during infection and stimulation of the host immune response. However, lipid S and LTA have different behaviours in the immune response, since lipid S is able to stimulate the murine macrophage-like cell line (J774.2) and peritoneal and splenic macrophages, producing higher concentrations of IL-1b, IL-6, TNFa and nitric oxide than LTA or peptidoglycan [26] . This indicates that S. epidermidis lipid S has a greater immunogenic and inflammatory capacity than LTA. It is not clear why lipid S is released during the growth of S. epidermidis. However, during biosynthesis of LTA several molecules are produced with different lengths, including lipid S. Lai et al. [9] suggested that the <10 kDa fraction contains lipid S (not determined). However, S. aureus LTA, LTA purified from the S. epidermidis membrane, or commercial LTA from other staphylococcal species also inhibited the production of TNFa induced by poly I:C, although LTAs from Streptococcus faecalis and Bacillus subtilis are not active [9] . The above indicates that LTA or lipid S is indistinctly recognized by the TLR2 of keratinocytes to inhibit TNFa production.
The use of beneficial bacteria as a probiotic agent for the skin represents an alternative means of care or a method for treating diseases of the skin. Activated Lactobacillus acidophilus was used as a treatment against mild to moderate vernal keratoconjunctivitis (an allergic eye disease) [27] . Lactic acid bacteria, such as Lactobacillus paracasei, L. brevis or L. fermentum, were proposed as ingredients in skin-care products [28] . Streptococcus salivarius K12 stimulates an anti-inflammatory response in the skin [29] . A bacterial extract of the Gram-negative bacteria Vitreoscilla filiformis, when applied to lesions of patients with atopic dermatitis, showed a beneficial effect [30] . S. epidermidis LTA stimulates keratinocytes to produce miR-143, which inhibits P. acnes infection in the skin [10] . These findings indicate that it is possible to use pure LTA or S. epidermidis as a therapeutic alternative for the treatment or control of skin inflammations. However, the substantial contribution of our work is the determination that not all of the isolates of S. epidermidis (clinical or commensal) release LTA.
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